PURE Bioscience, Inc. (PURE) Operating margin 2017–2026
PURE Bioscience, Inc. (PURE) operating margin by fiscal year — reported operating income divided by reported revenue.
-89.9%FY2026 · since FY2017: -328.1% → -89.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -89.9% | +13.3 pp |
| FY2025 | -103.2% | +59.4 pp |
| FY2024 | -162.6% | +47.5 pp |
| FY2023 | -210.1% | -9.1 pp |
| FY2022 | -201.0% | -142.1 pp |
| FY2021 | -58.8% | -58.9 pp |
| FY2020 | 0.1% | +292.8 pp |
| FY2019 | -292.8% | +104.2 pp |
| FY2018 | -397.0% | -68.8 pp |
| FY2017 | -328.1% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More PURE financial trends
PURE RevenuePURE Net incomePURE Net marginPURE Gross profitPURE Gross marginPURE Operating incomePURE Operating cash flowPURE Free cash flowPURE Capital expendituresPURE Return on equityPURE Stock buybacksPURE Dividends paidPURE Total assetsPURE Total liabilitiesPURE Shareholders’ equityPURE overview →